Physician profile
Jonathan K Wise
NPI 1932186483
$20,369.47
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $2,528 · 2021: $1,535.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $15,268.26 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,553.75 | 2019-2021 | |
| Eli Lilly and Company | $903.46 | 2019 | |
| Novo Nordisk INC | $692.50 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $401.19 | 2019-2020 | |
| Abbott Laboratories | $265.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $198.41 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $168.54 | 2019-2020 | |
| Lilly USA, LLC | $156.89 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $128.65 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.13 | 2019-2020 | |
| Allergan, INC. | $99.99 | 2019 | |
| Amgen INC. | $90.52 | 2019-2020 | |
| Corcept Therapeutics | $77.78 | 2019-2020 | |
| Medtronic Minimed, INC. | $51.91 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.78 | 2019-2020 | |
| Amarin Pharma, INC. | $32.34 | 2019-2020 | |
| Radius Health, INC. | $27.48 | 2019 | |
| Amneal Pharmaceuticals LLC | $27.15 | 2019-2020 | |
| Ethicon US, LLC | $26.24 | 2020 | |
| Becton, Dickinson and Company | $17.60 | 2019 | |
| Pfizer INC. | $17.23 | 2019 | |
| Dexcom, INC. | $12.13 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Research and ownership
$67,752.16 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.